Business

SMi's 3rd Annual AI in Drug Discovery Conference

14 - 15 March 2022, London, UK.
SMi Group presents its 3rd Annual AI in Drug Discovery Conference, taking place on the 14th and 15th March 2022 in London, UK. With the recent pandemic highlighting the need for rapid drug discovery, AI has become an area of increased interest. This is driven by the ability to discover drugs through the use of machine and deep learning.

WHO grants prequalification of Actemra/RoActemra for patients with severe or critical COVID-19

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that Actemra®/RoActemra® (tocilizumab) intravenous (IV) has been granted World Health Organization (WHO) prequalification. Prequalification is a confirmation by WHO that Actemra/RoActemra meets the WHO standards for quality, safety and efficacy for the treatment of COVID-19 in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation.

Sanofi unveils new corporate brand and logo - unites the company under one purpose and a single identity

Sanofi unveiled a new bold and unifying corporate brand that supports the modernization and transformation the company launched in December 2019.

Over the last 50 years, Sanofi has grown into a diverse, global healthcare leader, with a rich heritage of patient-centric scientific discovery.

Pfizer receives CHMP positive opinion for novel COVID-19 oral treatment

Pfizer Inc. (NYSE: PFE) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion recommending the conditional marketing authorization (CMA) of Pfizer's PAXLOVID™ (nirmatrelvir [PF-07321332] tablets and ritonavir tablets) for the treatment of COVID-19 in adults who do not require supplemental oxygen and who are at increased risk for progressing to severe COVID-19.

Pfizer and BioNTech initiate study to evaluate Omicron-based COVID-19 vaccine in adults 18 to 55 years of age

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced the initiation of a clinical study to evaluate the safety, tolerability and immunogenicity of an Omicron-based vaccine candidate in healthy adults 18 through 55 years of age. The study will have three cohorts examining different regimens of the current Pfizer-BioNTech COVID-19 vaccine or an Omicron-based vaccine.

Pfizer and BioNTech publish data from two laboratory studies on COVID-19 vaccine-induced antibodies ability to neutralize SARS-CoV-2 Omicron variant

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced the publication of new results from two laboratory studies demonstrating that three doses of the Pfizer-BioNTech COVID-19 Vaccine (BNT162b2) elicited antibodies that neutralize the Omicron variant (B.1.1.529).

R2G Launches a New Global Annual Survey: Global Digital Health Business Outlook - 2022

R2G launches a new Global Annual Digital Health Business Survey - 2022 to assess the digital health industry outlook in 2022. The survey is conducted by R2G on an on-going basis annually which focuses on gathering opinions from digital health decision makers on how the digital health industry will evolve in the coming year.

Business

More Pharma News ...